DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS
  1. Home
  2. Research Programs
  3. Autism
  4. Research Highlights/News
  5. 2017 Autism Research Program

Autism

NEWS RELEASE

Released: May 2, 2017

Defense Health Program
Department of Defense Autism Research Program
Anticipated Funding Opportunities for Fiscal Year 2017 (FY17)

Due to the current Continuing Resolution, the FY17 Defense Appropriations bill has not been passed. Although funds have not been appropriated for the Department of Defense Autism Research Program (ARP), the ARP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY17 funding opportunities.

FY17 ARP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on Grants.gov in May 2017. Pre-application and application deadlines will be available when the Program Announcements are released. This pre-announcement should not be construed as an obligation by the Government, and funding of research projects received in response to these Program Announcements is contingent on the availability of Federal funds appropriated for the ARP.

As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) Research and Development Directorate (J9) manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).
Award Mechanism PI Eligibility Key Mechanism Elements Funding
Clinical Translational Research Award Investigators at or above the level of Assistant Professor (or equivalent)
  • Supports early-phase, proof-of-principle translational studies with the potential to have a major impact on the treatment and/or management of autism spectrum disorder (ASD).
  • Preliminary data relevant to the proposed project are required, but do not have to be generated by the applying investigator.
  • Pre-application is required; application submission is by invitation only.
  • Maximum funding of $500,000 for direct costs (plus indirect costs)
  • Maximum period of performance is 3 years
Clinical Trial Award Investigators at or above the level of Associate Professor (or equivalent), or

Nested Young Investigator Option:
Investigators at or above the level of Associate Professor (or equivalent) may collaborate on a single application with a young investigator (at the level of postdoctoral fellow up to early-career independent faculty) that meets the following criteria at the application submission deadline date:
  • Must be within the first year of postdoctoral fellowship by the application deadline
  • Is no more than 7 years from the receipt of a terminal degree
  • Has the freedom to commit at least 50% time to the project
  • Supports research with the potential to have a major impact on the treatment and/or management of ASD.
  • Preliminary data relevant to the proposed project are required.
  • Pre-application is required; application submission is by invitation only.
  • Nested Young Investigator Option supports the development of young investigators pursuing or wishing to pursue clinical trials.
  • Maximum funding of $1,000,000 for direct costs (plus indirect costs)
  • Maximum period of performance is 4 years

Nested Young Investigator Option:
  • Maximum funding of $1,300,000 for direct costs (plus indirect costs)
  • Maximum period of performance is 4 years
Idea Development Award Investigators at or above the level of Assistant Professor (or equivalent), or

Multiple PI Option: Up to two investigators may collaborate on a single application, both of whom will be recognized as a Principal Investigator and receive a separate award.
  • Preproposal is required; application submission is by invitation only.
  • Supports the development of innovative, high-impact ideas that advance the understanding of ASD and ultimately lead to improved outcomes.
  • Preliminary data are required.
  • Clinical trials are not allowed.
  • Maximum funding of $500,000 for direct costs (plus indirect costs)
  • Maximum period of performance is 3 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

Applications must be submitted through the federal government�s single-entry portal, Grants.gov. Submission deadlines are not available until the Program Announcements are released. For email notification when Program Announcements are released, subscribe to program-specific news and updates under �Email Subscriptions� on the eBRAP homepage at https://eBRAP.org. For more information about the ARP or other CDMRP-administered programs, please visit the CDMRP website (htCDMRP.HEALTH.MILmy.mil).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


Last updated Tuesday, November 12, 2024